Loading...

Allen-Auerbach Martin

TitleHealth Sciences Associate Clinical Professor
InstitutionUniversity of California Los Angeles
DepartmentMolecular & Medical Pharmacology
Address200 Medical Plaza Suite B-114
Los Angeles CA 90095
Phone(310) 983-1444
vCardDownload vCard
    Other Positions
    TitleMedical Director


    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Brown MS, Kim GHJ, Chu GH, Ramakrishna B, Allen-Auerbach M, Fischer CP, Levine B, Gupta PK, Schiepers CW, Goldin JG. Quantitative bone scan lesion area as an early surrogate outcome measure indicative of overall survival in metastatic prostate cancer. J Med Imaging (Bellingham). 2018 Jan; 5(1):011017. PMID: 29340285.
      View in: PubMed
    2. Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach M, Czernin J, Herrmann K. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med. 2018 Mar; 59(3):434-441. PMID: 29242398.
      View in: PubMed
    3. Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach M, Herrmann K. Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented. J Nucl Med. 2017 Nov; 58(11):1793-1796. PMID: 28473600.
      View in: PubMed
    4. Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Pöppel TD, Rischpler C, Schwarzenböck S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M. 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. J Nucl Med. 2017 Oct; 58(10):1617-1623. PMID: 28408531.
      View in: PubMed
    5. Keu KV, Witney TH, Yaghoubi S, Rosenberg J, Kurien A, Magnusson R, Williams J, Habte F, Wagner JR, Forman S, Brown C, Allen-Auerbach M, Czernin J, Tang W, Jensen MC, Badie B, Gambhir SS. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci Transl Med. 2017 01 18; 9(373). PMID: 28100832.
      View in: PubMed
    6. Barrio M, Czernin J, Yeh MW, Palma Diaz MF, Gupta P, Allen-Auerbach M, Schiepers C, Herrmann K. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients. Nucl Med Commun. 2016 Dec; 37(12):1290-1296. PMID: 27612034.
      View in: PubMed
    7. Barrio MJ, Spick C, Radu CG, Lassmann M, Eberlein U, Allen-Auerbach M, Schiepers C, Slavik R, Czernin J, Herrmann K. Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway. J Nucl Med. 2017 Mar; 58(3):374-378. PMID: 27811125.
      View in: PubMed
    8. Fendler WP, Barrio M, Spick C, Allen-Auerbach M, Ambrosini V, Benz M, Bluemel C, Grewal RK, Lapa C, Miederer M, Nicolas G, Schuster T, Czernin J, Herrmann K. 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients. J Nucl Med. 2017 Feb; 58(2):307-311. PMID: 27539839.
      View in: PubMed
    9. Werner RA, Bluemel C, Lassmann M, Kudlich T, Higuchi T, Lopci E, Allen-Auerbach M, Colletti PM, Rubello D, Zatelli MC, Herrmann K. SPECT- and PET-based patient-tailored treatment in neuroendocrine tumors: a comprehensive multidisciplinary team approach. Clin Nucl Med. 2015 May; 40(5):e271-7. PMID: 25642915.
      View in: PubMed
    10. Lapa C, Werner RA, Bluemel C, Lueckerath K, Muegge DO, Strate A, Haenscheid H, Schirbel A, Allen-Auerbach M, Bundschuh RA, Buck AK, Herrmann K. Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy. EJNMMI Res. 2014; 4:74. PMID: 25977880; PMCID: PMC4412196.
    11. Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, Schiepers C, Mosessian S, Phelps ME, Allen-Auerbach M. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective. J Nucl Med. 2015 Jan; 56(1):70-5. PMID: 25500825.
      View in: PubMed
    12. Karantanis D, Kalkanis D, Czernin J, Herrmann K, Pomykala KL, Bogsrud TV, Subramaniam RM, Lowe VJ, Allen-Auerbach M. Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians. J Nucl Med. 2014 Dec; 55(12):1925-9. PMID: 25453041; PMCID: PMC4324619.
    13. Werner RA, Bluemel C, Allen-Auerbach M, Higuchi T, Herrmann K. 68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs. Ann Nucl Med. 2015 Jan; 29(1):1-7. PMID: 25139472; PMCID: PMC4306729.
    14. Wieder HA, Lassmann M, Allen-Auerbach M, Czernin J, Herrmann K. Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters. World J Radiol. 2014 Jul 28; 6(7):480-5. PMID: 25071888; PMCID: PMC4109099.
    15. Karantanis D, Kalkanis D, Allen-Auerbach M, Herrmann K, Pomykala KL, Bogsrud TV, Lowe VJ, Czernin J. Oncologic PET/CT interpretation and reporting approaches. Survey in clinical practice. Nuklearmedizin. 2014; 53(2):19-25. PMID: 24473996.
      View in: PubMed
    16. Lizarraga KJ, Allen-Auerbach M, Czernin J, DeSalles AA, Yong WH, Phelps ME, Chen W. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. J Nucl Med. 2014 Jan; 55(1):30-6. PMID: 24167081.
      View in: PubMed
    17. Allen-Auerbach M, de Vos S, Czernin J. PET/computed tomography and lymphoma. Radiol Clin North Am. 2013 Sep; 51(5):833-44. PMID: 24010908.
      View in: PubMed
    18. Czernin J, Allen-Auerbach M, Nathanson D, Herrmann K. PET/CT in Oncology: Current Status and Perspectives. Curr Radiol Rep. 2013; 1:177-190. PMID: 24883234.
      View in: PubMed
    19. Karantanis D, Kalkanis D, Allen-Auerbach M, Bogsrud TV, Subramaniam RM, Danielson A, Lowe VJ, Czernin J. Oncologic 18F-FDG PET/CT: referring physicians' point of view. J Nucl Med. 2012 Oct; 53(10):1499-505. PMID: 22917886.
      View in: PubMed
    20. Karantanis D, Allen-Auerbach M, Czernin J. Squamous papilloma of the oral cavity and oropharynx on 18F-FDG PET/CT imaging. Clin Nucl Med. 2012 May; 37(5):e98-9. PMID: 22475925.
      View in: PubMed
    21. Brown MS, Chu GH, Kim HJ, Allen-Auerbach M, Poon C, Bridges J, Vidovic A, Ramakrishna B, Ho J, Morris MJ, Larson SM, Scher HI, Goldin JG. Computer-aided quantitative bone scan assessment of prostate cancer treatment response. Nucl Med Commun. 2012 Apr; 33(4):384-94. PMID: 22367858; PMCID: PMC3294499.
    22. Walter F, Czernin J, Hall T, Allen-Auerbach M, Walter MA, Dunkelmann S, Federman N. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients? J Pediatr Hematol Oncol. 2012 Mar; 34(2):131-6. PMID: 22134608.
      View in: PubMed
    23. Herrmann K, Benz MR, Czernin J, Allen-Auerbach M, Tap WD, Dry SM, Schuster T, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clin Cancer Res. 2012 Apr 01; 18(7):2024-31. PMID: 22338012; PMCID: PMC3431618.
    24. Karantanis D, Allen-Auerbach M, Czernin J. Relationship among glycolytic phenotype, grade, and histological subtype in ovarian carcinoma. Clin Nucl Med. 2012 Jan; 37(1):49-53. PMID: 22157028.
      View in: PubMed
    25. Karantanis D, Allen-Auerbach M, Czernin J. Sources and resources for oncologists to help answer the question: is PET/CT appropriate for my patient? Hell J Nucl Med. 2012 Jan-Apr; 15(1):2-8. PMID: 22413105.
      View in: PubMed
    26. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach M. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med. 2011 Nov; 52(11):1684-1689. PMID: 22045706; PMCID: PMC5021512.
    27. Benz MR, Czernin J, Allen-Auerbach M, Dry SM, Sutthiruangwong P, Spick C, Radu C, Weber WA, Tap WD, Eilber FC. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response. Cancer. 2012 Jun 15; 118(12):3135-44. PMID: 22020872; PMCID: PMC3436595.
    28. Walter F, Federman N, Apichairuk W, Nelson S, Phelps ME, Allen-Auerbach M, Walter MA, Czernin J. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients. Pediatr Hematol Oncol. 2011 Oct; 28(7):579-87. PMID: 21936620.
      View in: PubMed
    29. Czernin J, Benz MR, Allen-Auerbach M. Breast cancer. Methods Mol Biol. 2011; 727:141-70. PMID: 21331933.
      View in: PubMed
    30. Benz MR, Dry SM, Eilber FC, Allen-Auerbach M, Tap WD, Elashoff D, Phelps ME, Czernin J. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. J Nucl Med. 2010 Aug; 51(8):1174-81. PMID: 20660389; PMCID: PMC3197812.
    31. Benz MR, Czernin J, Tap WD, Eckardt JJ, Seeger LL, Allen-Auerbach M, Dry SM, Phelps ME, Weber WA, Eilber FC. FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas. Sarcoma. 2010; 2010:143540. PMID: 20414348; PMCID: PMC2855986.
    32. Ribas A, Benz MR, Allen-Auerbach M, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med. 2010 Mar; 51(3):340-6. PMID: 20150263.
      View in: PubMed
    33. Czernin J, Benz MR, Allen-Auerbach M. PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. Eur J Radiol. 2010 Mar; 73(3):470-80. PMID: 20097498.
      View in: PubMed
    34. Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach M, Elashoff D, Phelps ME, Weber WA, Eilber FC. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer. 2010 Jan 15; 116(2):451-8. PMID: 19924789; PMCID: PMC3188986.
    35. Allen-Auerbach M, Weber WA. Measuring response with FDG-PET: methodological aspects. Oncologist. 2009 Apr; 14(4):369-77. PMID: 19357228.
      View in: PubMed
    36. Benz MR, Czernin J, Allen-Auerbach M, Tap WD, Dry SM, Elashoff D, Chow K, Evilevitch V, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009 Apr 15; 15(8):2856-63. PMID: 19351756; PMCID: PMC4068269.
    37. Czernin J, Benz MR, Allen-Auerbach M. PET Imaging of Prostate Cancer Using C-Acetate. PET Clin. 2009 Apr; 4(2):163-72. PMID: 21984877.
      View in: PubMed
    38. Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach M. Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma. Mol Imaging Biol. 2009 Jul-Aug; 11(4):269-74. PMID: 19326177; PMCID: PMC2693779.
    39. Lipshutz GS, Mihara N, Wong R, Wallace WD, Allen-Auerbach M, Dorigo O, Rao PN, Pham PC, Pham PT. Death from metastatic donor-derived ovarian cancer in a male kidney transplant recipient. Am J Transplant. 2009 Feb; 9(2):428-32. PMID: 19178417.
      View in: PubMed
    40. Benz MR, Allen-Auerbach M, Eilber FC, Chen HJ, Dry S, Phelps ME, Czernin J, Weber WA. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008 Oct; 49(10):1579-84. PMID: 18794268; PMCID: PMC4068272.
    41. Benz MR, Evilevitch V, Allen-Auerbach M, Eilber FC, Phelps ME, Czernin J, Weber WA. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med. 2008 Jul; 49(7):1038-46. PMID: 18552153; PMCID: PMC4070847.
    42. Allen-Auerbach M, de Vos S, Czernin J. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin North Am. 2008 Mar; 46(2):199-211, vii. PMID: 18619376.
      View in: PubMed
    43. Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, Eilber FR, Eckardt JJ, Elashoff RM, Phelps ME, Czernin J, Eilber FC. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2008 Feb 01; 14(3):715-20. PMID: 18245531.
      View in: PubMed
    44. Saisho Y, Butler AE, Meier JJ, Monchamp T, Allen-Auerbach M, Rizza RA, Butler PC. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin Anat. 2007 Nov; 20(8):933-42. PMID: 17879305; PMCID: PMC2680737.
    45. Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M, Czernin J, Schiepers C. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med. 2007 Feb; 48(2):214-20. PMID: 17268017.
      View in: PubMed
    46. Halpern BS, Yeom K, Fueger BJ, Lufkin RB, Czernin J, Allen-Auerbach M. Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions. Eur J Radiol. 2007 May; 62(2):199-204. PMID: 17223003.
      View in: PubMed
    47. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007 Jan; 48 Suppl 1:78S-88S. PMID: 17204723.
      View in: PubMed
    48. Allen-Auerbach M, Yeom K, Park J, Phelps M, Czernin J. Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer. J Nucl Med. 2006 Feb; 47(2):298-301. PMID: 16455636.
      View in: PubMed
    49. Fueger BJ, Weber WA, Quon A, Crawford TL, Allen-Auerbach M, Halpern BS, Ratib O, Phelps ME, Czernin J. Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol. 2005 Sep-Oct; 7(5):369-76. PMID: 16220355.
      View in: PubMed
    50. Kim JH, Czernin J, Allen-Auerbach M, Halpern BS, Fueger BJ, Hecht JR, Ratib O, Phelps ME, Weber WA. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med. 2005 Apr; 46(4):587-95. PMID: 15809480.
      View in: PubMed
    51. Allen-Auerbach M, Quon A, Weber WA, Obrzut S, Crawford T, Silverman DH, Ratib O, Phelps ME, Czernin J. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol. 2004 Nov-Dec; 6(6):411-6. PMID: 15564152.
      View in: PubMed
    52. Allen-Auerbach M, Schöder H, Johnson J, Kofoed K, Einhorn K, Phelps ME, Kobashigawa J, Czernin J. Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients. J Heart Lung Transplant. 1999 Mar; 18(3):211-9. PMID: 10328146.
      View in: PubMed